1. Home
  2. In The News
  3. When it comes to Roundup and cancer, everybody's lobbying the regulators

When it comes to Roundup and cancer, everybody’s lobbying the regulators

March 28, 2019 in In The News

Legal NewsLine | By Daniel Fisher

Plaintiff-lawyer lobbying over glyphosate continues. An unusual news release by Health Canada in January reveals how much pressure one plaintiff lawyer, Brent Wisner, has brought against the Canadian agency responsible for evaluating the safety of drugs and pesticides. In it, Health Canada said it had rejected objections to its refusal to reclassify glyphosate that were filed by eight groups allied with Wisner’s law firm.

“Our scientists left no stone unturned in conducting this review,” Health Canada said. “No pesticide regulatory authority in the world currently considers glyphosate to be a cancer risk to humans at the levels at which humans are currently exposed.”

Click here to read more

Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on a cross-cutting issue like federal preemption which would effectively and largely end the U.S. Roundup™ litigation. The second scenario assumes that the Supreme Court either declines to hear the Hardeman case or issues a ruling in favor of plaintiff – in that case the company would activate its own claims administration program.

Read about the five-point plan here.